Weekly Recap | Bristol Myers Squibb +0.36%, CAR-T trial pauses in focus
I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) rose 0.36% this week to close at $66.82, beating the S&P 500 by around 0.27 percentage points. It opened Monday at $66.25 and dipped to $65.91 before rallying to $68.04 on Tuesday, then hit a weekly high of $68.24 on Thursday before settling at $66.82 on Friday. The week had a push-up-and-fade, rangebound shape.
The Week
Bristol Myers Squibb (BMY) rose 0.36% this week to close at $66.82, beating the S&P 500 by around 0.27 percentage points. It opened Monday at $66.25 and dipped to $65.91 before rallying to $68.04 on Tuesday, then hit a weekly high of $68.24 on Thursday before settling at $66.82 on Friday. The week had a push-up-and-fade, rangebound shape.
Key Events
On Monday the company presented results for the EXPLORER-LTE cohort of the MAVA-LTE study. On Tuesday a spokesperson said BMY had implemented a voluntary pause to review clinical data across its Zola-Cel programme; the same day Novartis halted eight Rap-Cel trials after three patient deaths, and BMY’s CAR-T autoimmune trials were also paused. Later in the week an analyst linked the trial freeze to the reported deaths, keeping attention on the safety and next steps for its CAR-T pipeline.
Analyst Ratings
A total of 29 institutions cover Bristol Myers Squibb: 7 rate it buy, 3 overweight, 17 hold, 1 sell, and 1 has no opinion. The consensus rating is buy, with a consensus target of $66.21, about 0.9% below the latest price. Targets range from $40.00 to $80.00, showing a wide spread. BMY ranks 2nd within its industry group of 205 pharmaceutical companies.
The Week Ahead
The macro calendar is busy next week, with US initial jobless claims, final-demand PPI and existing home sales due on Thursday 10 September. On the company side, the next earnings report is set for 29 October, with Q3 FY2026 results expected before market open; current estimates put EPS at $1.4612 and revenue at $12.7 billion. Updates on the paused CAR-T trials and any Zola-Cel data review conclusions are also worth watching.
In Short
This week’s upside came mainly from company-specific data and sector moves, while the Zola-Cel and CAR-T pauses added downside pressure. The analyst picture leans positive overall, with a buy consensus, yet the consensus target sits slightly below spot and the target range is wide. On the latest trading day, large and medium orders were net buyers while small orders were net sellers. The key follow-throughs are the safety assessment and restart timeline for the CAR-T trials, plus the October earnings print on the pipeline and revenue.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.